Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - Oppenheimer lowered its price target on Perspective Therapeutics Inc (NYSE:CATX) to $14.00 from $15.00 on Wednesday, while maintaining an Outperform rating on the stock. The new target still represents significant upside potential from the current price of $3.98, with analyst targets ranging from $6.00 to $20.50.
The price target reduction follows Perspective Therapeutics’ second-quarter 2025 financial results and business update released on Wednesday. The company highlighted recent clinical updates for its VMT-α-NET program from ASCO in May, with additional data expected at ESMO in October. According to InvestingPro analysis, the company’s overall financial health score is Fair, with particularly strong momentum metrics despite recent challenges.
Perspective Therapeutics reported progress on both its FAP and MC1R targeting programs, with patients actively being treated in both studies. The company ended the second quarter with $192 million in cash, which is expected to support operations into late 2026. InvestingPro data shows the company maintains a strong liquidity position with a current ratio of 17.02, though it’s currently burning through cash rapidly.
Oppenheimer updated its financial model to reflect actual results, including increased estimates for R&D costs, and added a financing projection for 2026. The firm cited increased spending and dilution as reasons for the price target reduction.
Despite the lower price target, Oppenheimer reiterated its Outperform rating, expressing continued enthusiasm about Perspective Therapeutics’ opportunity to demonstrate best-in-class efficacy and safety with VMT-α-NET and validate the opportunity for FAP.
In other recent news, Perspective Therapeutics, Inc. has announced that updated data from its [212Pb]VMT-α-NET program for treating neuroendocrine tumors will be presented at the European Society of Medical Oncology Congress in October 2025. This presentation will include mature safety and preliminary efficacy data from 44 patients in the first two dose-finding cohorts of the clinical trial. RBC Capital recently raised the company’s stock price target to $16 from $15, maintaining an Outperform rating, following data updates from the company’s NET program presented at the American Society of Clinical Oncology. The analysts highlighted the program’s competitive objective response rate and best-in-class safety profile.
Additionally, Oppenheimer adjusted its outlook on Perspective Therapeutics, reducing the stock price target to $15 from $16 but maintaining an Outperform rating. This revision was based on the company’s first-quarter results and business updates, including active enrollment in clinical programs for neuroendocrine tumors, melanoma, and familial adenomatous polyposis. The company also announced the results of its 2025 Annual Meeting of Stockholders, where a quorum was reached, and five board members were elected to serve until the 2026 Annual Meeting. These recent developments continue to shape the outlook for Perspective Therapeutics as it progresses in its clinical endeavors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.